Makers of over-the-counter drugs may soon pay for federal review of their products, just like pharmaceutical makers. And they’re fine with the change.
After years of discussion, the Food and Drug Administration appears poised to make that change as part of a sweeping overhaul of its regulations for OTC products. But during a stakeholder meeting on the topic Wednesday afternoon, it was clear that many specifics about the program will be foggy until Congress acts.
About the Author Reprints
